• News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • FREE newsletter subscription
  • Search
  • Menu Menu
International Hospital
  • AI
  • Cardiology
  • Oncology
  • Neurology
  • Genetics
  • Orthopaedics
  • Research
  • Surgery
  • Innovation
  • Medical Imaging
  • MedTech
  • Obs-Gyn
  • Paediatrics

Archive for category: Corona News

Corona News

Psychologist urges people to accept grief and not disengage amid Covid-19 pandemic

, 26 August 2020/in Corona News, E-News /by 3wmedia

As the COVID-19 pandemic upends life as people know it, changing daily routines, limiting social interactions and shaking their sense of safety, a mental health experts from U.S. hospital Cleveland Clinic’s Mellen Center is stressing that it is perfectly acceptable to feel sad about all of it.
She points out that grief is a natural response to loss – whether it is the loss of a loved one, or the loss of a sense of normalcy.
“We are experiencing a lot of disappointment right now – in both small and big ways – and grief is going to be a factor,” says clinical health psychologist Amy Sullivan, PsyD, ABPP.
“It’s really important that we process this and stay connected to other people in safe ways,” she adds.
Regarding how people should go about dealing with all of these difficult and unexpected feelings bubbling up, she says there is no right or wrong way. However, she offers four suggestions that can help people to cope with current events.
1. Look through the lens of grief and process emotions
She says that the stages of grief can provide a helpful framework for navigating these complex emotions. Experts recognize these stages as denial, anger, bargaining, despair, and acceptance. However, these experts also know that people do not step neatly from one stage to the next in this exact order, she says.
“Grief can come in waves and change on a very regular basis. Our feelings can change on a daily, or even an hourly, basis,” she explains.
Dr. Sullivan adds it is normal to go from feeling despair one day to anger the next.
“The first thing we need to do is to recognize that it is normal to have these waves of emotions that are happening on a regular basis,” Dr. Sullivan says.
Next, she says, acknowledge the loss whether it is knowing or losing someone with COVID-19, losing jobs, missing friends or family.
“Those are all very sad, difficult things for people to manage,” Dr. Sullivan says.
“Feel what you are feeling – whether it is being overwhelmed, anxious, powerless or anything else, it can help to identify and name these emotions,” she advises.
“It can be quite powerful to sit with those feelings for a few moments – to really recognize those emotions and normalize them,” she says.
However, she advises people to set a time limit on this, suggesting they give themselves five minutes to feel that emotion, and then move on to something that they know is a positive coping skill for them.
“It is important for us to accept where our feelings are at the moment and process through them, and then move into a more positive position of acceptance,” she says.
She says this can be done by identifying their own best coping mechanisms
“This is a time when people need to become innovative and develop their own individual sense of coping that works for them during this time,” she says. Examples might include deep breathing, mindfulness exercises, journaling, talking with another person, or going for a walk.
“If it comes to a point where someone cannot handle these feelings on their own, they need to seek mental health help,” Dr. Sullivan says.
2. Fight the urge to disengage
Dr. Sullivan stresses that staying connected is a powerful tool for coping during hard times. Whether that comes in the form of video chatting or sending a good old-fashioned letter, staying in touch with family, friends, neighbours and coworkers can help people to keep a positive attitude, she says.
She adds that many trained mental and behavioural health professionals are currently seeing patients through virtual visits, so that if people are having trouble coping, this could be a solution.
3. Focus on what can be controlled
Dr. Sullivan says that when there is so much uncertainty about the future, it is easy for people to get carried away, playing out the worst-case scenarios in their heads, for example worrying about themselves or someone else getting COVID-19, or wondering if things will ever get back to normal.
“Anticipating negative events can bring a sense of anxiety or fear,” Dr. Sullivan says.
She advises that, instead of agonizing over the things that cannot be known or controlled, people should be aware of what they do have control over. For example, they can choose how much news or social media they consume in a day, and they can decide what they eat. She recommends being mindful about these choices, and focusing on staying in the present.
4. Be open to joy
Lastly, Dr. Sullivan advises people to find joy and gratitude in the small things, like a video chat with family members, or the rush of fresh air when they open a window or step outside. She adds that if they are under a lockdown order, they can find ways to appreciate the opportunity to step back from the hustle and bustle of everyday life and being home.

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:35:292020-08-26 14:35:34Psychologist urges people to accept grief and not disengage amid Covid-19 pandemic

Johnson & Johnson aims to produce a billion doses of COVID-19 vaccine

, 26 August 2020/in Corona News, E-News /by 3wmedia

Johnson & Johnson has announced the selection of a lead COVID-19 vaccine candidate on which it expects to initiate human clinical studies by September at the latest with the first batches of the vaccine available for emergency use authorization in early 2021.
In addition, the company announced the significant expansion of the existing partnership between the Janssen Pharmaceutical Companies of Johnson & Johnson and the Biomedical Advanced Research and Development Authority (BARDA).
Johnson & Johnson also said the company will rapidly scale up its manufacturing capacity with the goal of providing a global supply of more than one billion doses of the vaccine.
Through the new partnership, BARDA and Johnson & Johnson together have committed more than $1 billion of investment to co-fund vaccine research, development, and clinical testing. The company says will use its validated vaccine platform and is allocating resources, including personnel and infrastructure globally, as needed, to focus on these efforts.
BARDA is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services.
Commenting on the initiative, Alex Gorsky, Chairman and Chief Executive Officer, Johnson & Johnson, said: “The world is facing an urgent public health crisis and we are committed to doing our part to make a COVID-19 vaccine available and affordable globally as quickly as possible. As the world’s largest healthcare company, we feel a deep responsibility to improve the health of people around the world every day. Johnson & Johnson is well positioned through our combination of scientific expertise, operational scale and financial strength to bring our resources in collaboration with others to accelerate the fight against this pandemic.”
The company’s expansion of its manufacturing capacity will include the establishment of new U.S. vaccine manufacturing capabilities and scaling up capacity in other countries. The additional capacity will assist in the rapid production of a vaccine and will enable the supply of more than one billion doses of a safe and effective vaccine globally.
Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson, said: “We are very pleased to have identified a lead vaccine candidate from the constructs we have been working on since January. We are moving on an accelerated timeline toward Phase 1 human clinical trials at the latest by September 2020 and, supported by the global production capability that we are scaling up in parallel to this testing, we expect a vaccine could be ready for emergency use in early 2021.” In addition to the vaccine development efforts, BARDA and Johnson & Johnson have also expanded their partnership to accelerate Janssen’s ongoing work in screening compound libraries, including compounds from other pharmaceutical companies. The company’s aim is to identify potential treatments against the novel coronavirus. Johnson & Johnson and BARDA are both providing funding as part of this partnership. These antiviral screening efforts are being conducted in partnership with the Rega Institute for Medical Research (KU Leuven/University of Leuven), in Belgium.

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:35:292020-08-26 14:35:38Johnson & Johnson aims to produce a billion doses of COVID-19 vaccine

Superbugs and failing drugs

, 26 August 2020/in Corona News, E-News, Editors' Picks /by 3wmedia

Bacteria that develop resistance to antibiotic drugs – superbugs – pose a major global health threat to humanity. In a concerted effort to stave off this threat, several global programmes have been established and numerous new research initiatives are being carried out. Whether they are successful is yet to be seen. International Hospital reports.
Antimicrobial or antibiotic resistance is a major emerging global health threat which continues to escalate around the world. In the EU it is responsible for around 33,000 deaths each year according to the European Commission [1] and is estimated to cost the EU EUR 1.5 billion per year in healthcare costs and productivity losses.
In the United States, the Centers for Disease Control and Prevention (CDC) estimates that more than 2.8 million antibiotic-resistant infections occur in the country each year, and more than 35,000 people die as a result [2].
In the CDC’s 2019 Antimicrobial Resistance Threats Report, Robert R. Redfield, M.D., Director of the CDC, emphasises that we should stop referring to a coming post-antibiotic era. “It’s already here,” he says. “You and I are living in a time when some miracle drugs no longer perform miracles and families are being ripped apart by a microscopic enemy. The time for action is now and we can be part of the solution.”
So, what exactly is antimicrobial resistance (AMR)? Simply put, antimicrobial resistance occurs when microorganisms – such as bacteria, viruses, fungi, protozoa and helminths (worm-like parasites) – mutate or develop a resistance gene when they are exposed to antimicrobial drugs, such as antibiotics, antifungals, antivirals, antimalarials, and antihelminthics. As a result, the drugs become ineffective and infections persist in the body, increasing the risk of morbidity and mortality as well as the spread of the disease to others.
The issue is of such global importance that a political declaration was endorsed by Heads of State at the United Nations General Assembly in New York in September 2016 signalling the world’s commitment to taking a broad, coordinated approach to address the root causes of antimicrobial resistance across multiple sectors, especially human health, animal health and agriculture.
In 2015, the World Health Organization (WHO) established the Global Antimicrobial Resistance and Use Surveillance System (GLASS) [3]. The system calls on countries to monitor and report on antibiotic resistance. The WHO noted in a report published June 1 this year, that in the past three years, participation has grown exponentially. GLASS now aggregates data from more than 64,000 surveillance sites with more than 2 million patients enrolled from 66 countries across the world. In 2018 the number of surveillance sites was 729 across 22 countries.
Hanan Balkhy, Assistant Director-General for antimicrobial resistance at WHO, explained: “The enormous expansion of countries, facilities and patients covered by the new AMR surveillance system allows us to better document the emerging public health threat of AMR.”
On the back of this data, the Organization notes that high rates of resistance among antimicrobials frequently used to treat common infections, such as urinary tract infections or some forms of diarrhoea, indicate that the world is running out of effective ways to tackle these diseases. For instance, the rate of resistance to ciprofloxacin, an antimicrobial frequently used to treat urinary tract infections, varied from 8.4% to 92.9% in 33 reporting countries.
In addition, the WHO expressed concern that the trend will further be fuelled by the inappropriate use of antibiotics during the COVID-19 pandemic. The Organization points out that evidence shows that only a small proportion of COVID-19 patients need antibiotics to treat subsequent bacterial infections and, as such, has issued guidance [4] not to provide antibiotic therapy or prophylaxis to patients with mild COVID-19 or to patients with suspected or confirmed moderate COVID-19 illness unless there is a clinical indication to do so.
Solutions
What can be done to counter AMR? Although antimicrobial resistance occurs naturally over time, usually through genetic changes, there are a number of countermeasures. Primarily, healthcare practitioners should reduce the misuse and overuse of antimicrobials which are accelerating AMR. The WHO notes, for example, that in many places, antibiotics are overused and misused in people and animals, and often given without professional oversight. Examples of misuse include when they are taken by people with viral infections like colds and flu, and when they are given as growth promoters in animals or used to prevent diseases in healthy animals.

CDC’s 2019 Antimicrobial Resistant Threats Report

The CDC’s 2019 AR Threats Report lists 18 antibiotic-resistant bacteria and fungi in three categories based on the level of concern to human health – urgent, serious, and concerning. The ‘urgent’ list includes the following five threats:
Carbapenem-resistant Acinetobacter
Carbapenem-resistant Acinetobacter cause pneumonia and wound, bloodstream, and urinary tract infections. Nearly all these infections happen in patients who recently received care in a healthcare facility. They are estimated to have caused 700 deaths in the US in 2017.
Candida auris
C. auris is an emerging multidrug-resistant yeast. It can cause severe infections and spreads easily between hospitalized patients and nursing home residents.
Clostridioides difficile
C. difficile causes life-threatening diarrhoea and colitis (an inflammation of the colon), mostly in people who have had both recent medical care and antibiotics. Estimated death per year in the US: 12,800.
Carbapenem-resistant Enterobacteriaceae (CRE)
CRE are a major concern for patients in healthcare facilities. Some Enterobacteriaceae are resistant to nearly all antibiotics, leaving more toxic or less effective treatment options. Estimated deaths in the US in 2017: 1,100.
Drug-resistant Neisseria gonorrhoeae
N. gonorrhoeae causes the sexually transmitted disease gonorrhoeae that can result in life-threatening ectopic pregnancy and infertility, and can increase the risk of getting and giving HIV.
See the report for the complete list. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:35:292020-08-26 14:35:31Superbugs and failing drugs

Bedside patient monitoring system

, 26 August 2020/in Corona News, Product News /by 3wmedia

The Nellcor Bedside SpO2 System technology continuously monitors oxygen saturation (SpO2) and pulse rate for adult, paediatric and neonatal patients. The monitoring system gives clinicians instant access to comprehensive trending respiratory information, enabling them to detect subtle yet critical variations and respiratory complications earlier. The system features enhanced digital signal processing for precise SpO2 readings during low perfusion or other challenging conditions. It also incorporates an alarm management technology to differentiate between serious and minor events and reduce clinically insignificant oxygen desaturation alarms. The monitor further offers an intuitive, multicolour screen that is easy to read in any light and from many angles. Hospital technicians can set institutional defaults, replace the battery, perform diagnostics and generally maintain the monitor within the hospital, saving time and resources.
Read more

https://interhospi.com/wp-content/uploads/sites/3/2020/08/IH196_Covidien.jpg 66 150 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:34:092021-01-08 12:12:22Bedside patient monitoring system

Patient monitoring platform with additional measurement technologies

, 26 August 2020/in Corona News, Product News /by 3wmedia

The IntelliVue patient monitoring platform is now available with Masimo rainbow SET technology. Philips also offers its customers the option to add rainbow SET to existing IntelliVue monitors, and the company is working to integrate the technology into its Philips SureSigns and Philips Efficia patient monitoring platforms. In conjunction with the appropriate patient monitoring platform, Masimo rainbow SET technology analyses multiple wavelengths of light to accurately measure total hemoglobin (SpHb), oxygen content (SpOC), carboxyhemoglobin (SpCO), methemoglobin (SpMet) and Pleth Variability Index (PVI) noninvasively and continuously. Continuous monitoring of rainbow SpHb on a Philips monitor at the point-of-care provides clinicians with real-time visibility to changes in hemoglobin in between invasive blood sampling. To ensure that customers have choice of SpO2 pulse oximetry measurement technology, the company continues to offer Philips FAST SpO2 pulse oximetry and Covidien’s OxiMax SpO2 pulse oximetry, depending on the patient monitoring platform.
Read more

https://interhospi.com/wp-content/uploads/sites/3/2020/08/IH168_Philips.jpg 138 150 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:32:122021-01-08 12:10:54Patient monitoring platform with additional measurement technologies

ndd’s new inline filters offer additional protection against COVID-19 during lung function tests

, 26 August 2020/in Corona News, Product News /by 3wmedia

ndd Medical Technologies (ndd), a leading provider of diagnostic technology enabling healthcare professionals in the early detection of COPD and other chronic lung diseases, has introduced new single patient-use, inline filters for its lung function testing devices, in response to the global COVID-19 pandemic. Ensuring an added level of safety, the new filters can be used with ndd’s portable EasyOne spirometry range, including the EasyOne Air, EasyOne Pro, and EasyOne Pro LAB. EasyOne spirometers are popular among pulmonologists and medical researchers as they provide sensitive, reliable, real-time lung function results and diagnosis of chronic lung diseases, even at the point of care.
The EasyOne product line was originally designed with a strong focus on infection control with easy-to-wipe surfaces, single-use parts for anything that comes into contact with a patient’s breath, and ndd’s unique spirette and flow tube design which protects the flow sensor from cross-contamination. Now, when performing spirometry and testing of the diffusing capacity of the lungs for carbon monoxide (DLCO tests), the new EasyOne inline, single patient-use filters provide “double protection” for technicians and patients by keeping the ambient environment clean, without significantly affecting the EasyOne’s sensitivity.
ndd’s rigorous sensitivity tests have shown that the new inline filters do not significantly affect the device’s sensitivity and show comparable results in 24 waveform testing, (as required by ATS/ERS) and pass testing requirements. World-renowned medical research organizations – such as Johns Hopkins University, University Hospital Zurich and University of Cape Town – are partnering with ndd to assess the long-term lung damage caused by SARS-CoV-2.
Dr Trishul Siddharthan, Assistant Professor of Pulmonary and Critical Care Medicine at Johns Hopkins University, commented: “There is a lot of research underway to investigate the long-term effects of COVID-19. Our research group has been partnering with ndd thanks to the reliability of these spirometers in global settings and the ease of cleaning these devices during the pandemic to ensure safety.”
Prof. Friedrich Thienemann, General Medicine & Global Health research group, University of Cape Town and University Hospital Zurich, also noted: “In order to measure lung functions in resource-constrained settings like South African townships, one needs a device that is portable, point-of-care, easy-to-use, low-maintenance, and reliable without complicated calibration. EasyOne Pro LAB is that device.”
Incorporating ndd’s patented TrueFlow ultrasound technology, the EasyOne translates airflow into ultrasound signals which are measured by the sensors, so the patient’s breath does not come into contact with the sensors. This helps to prevent contamination and minimizes the cleaning required for safe use, while enabling a lifetime of calibration-free accuracy for flow and volume measurements.
To learn more about ndd, visit: www.nddmed.com
Read more

https://interhospi.com/wp-content/uploads/sites/3/2020/08/IH_PN_ndd.jpg 720 720 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:31:322021-01-08 12:10:16ndd’s new inline filters offer additional protection against COVID-19 during lung function tests

Xenios sees growing demand for ECMO devices

, 26 August 2020/in Corona News, Product News /by 3wmedia

Xenios AG, a company of the Fresenius Medical Care Group, reports that it has seen a significant growth in demand for its extracorporeal membrane oxygenation (ECMO) devices, which can be used for the treatment of patients who develop severe pneumonia and acute respiratory distress syndrome (ARDS) due to COVID-19 infection.
Jürgen Böhm, CMO of Xenios, explained that for critically ill COVID-19 patients with acute lung failure and refractory hypoxemia – despite use of standard therapy – “our treatment often remains the last therapeutic option and has been a lifesaver for many patients”.
Xenios’s ECMO therapy bypasses the function of the lungs. The patient’s blood is freed from carbon dioxide outside the body and enriched with oxygen. The lungs are thus given time to heal. Because of the increase of critically ill COVID-19 patients, more physicians are opting for ECMO therapy, and thus the increase in demand for Xenios’s ECMO devices.
To meet the demand, the company has increased production of its ECMO devices. “We have put many measures in place to maximize the utilization of our capacity to manufacture ECMO devices as well as patient kits. Our biggest challenge right now is the availability of specific components for our products,” said Andreas Terpin, CEO of Xenios.
For more information, visit: www.xenios-ag.com
Read more

https://interhospi.com/wp-content/uploads/sites/3/2020/08/PRODUCT_XENIOS.jpg 749 1000 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:31:322021-01-08 12:10:17Xenios sees growing demand for ECMO devices

Fujifilm’s Synapse 3D provides clinical decision support, speeds up workflow during COVID-19 emergency at Pisa University Hospital

, 26 August 2020/in Corona News, Product News /by 3wmedia

Pisa University Hospital has received support from Fujifilm Italia to improve and speed up the analysis of lung CT images which are important for the diagnosis of COVID-19. This has been possible thanks to an update by Fujifilm of the configuration of the Synapse 3D software used by emergency room radiologists.
The hospital says this new technological development has been useful to improving management of patients affected by COVID-19, during the emergency.
Synapse3D is a 3D medical image analysis system that uses Fujifilm’s image recognition technology to construct and analyze highprecision 3D images, compiled from tomographic images from CT and MRI. It delivers 3D visualization of medical images and has applications in image-based diagnosis and surgery simulation.
Synapse 3D delivers clinical value through fast, accurate, efficient and robust image processing for radiology, cardiology and surgical preoperation simulation.
It was developed in Japan (where it is named Synapse VINCENT) and it consists of more than 50 different processing modules.
The Synapse3D Lung Analysis/Airway module enables the analysis of density ranges in the lung in a quick, easy, objective and reproducible way.
At Pisa University Hospital the configuration of Synapse 3D was completed quickly, with the study of density ranges and a feasibility analysis carried out in a few days, meaning that this updated integrated workflow has been possible to use in the hospital since April 1.
The Pisa University Hospital had already set up three levels of assessing Coronavirus patients, and with the support of Synapse 3D software, doctors have had the ability to quickly and easily identify the stage of pneumonia, and therefore hospitalise patients accordingly:

  • normal hospitalisation for patients with mild pneumonia not requiring respiratory support
  • assessment by a pulmonologist or intensive care doctor for patients with moderate pneumonia to plan suitable respiratory support
  • intensive care assessment for patients with severe pneumonia with a view to transferring them to the intensive care unit

The density analysis provided by Synapse 3D has made it is possible to analyse the lung according to the different pixel densities of the CT images. Three groups were therefore defined based on different density ranges that allow the radiologist to evaluate the percentage of lung with lower density (emphysema), higher density (interstitial effort) and normal lung.
Dr. Chiara Romei, MD, PhD, Radiologist at the Pisa University Hospital, explained: “In a time of emergency such as this, it is crucial for us radiologists to detect accurate data as quickly as possible. Synapse 3D has enabled a quantitative analysis that is much faster and more objective than the visual analysis of the radiologist; in a couple of minutes it is possible to obtain data relating to the percentage of lung with greater and lesser density and to have a precise and objective, reproducible and shareable value.”
It is important to note that the data obtained by Synapse 3D does not replace the molecular diagnoses made through the nasopharyngeal swab (RT-PCR) and does not replace the analysis and diagnostic work by the radiologist, but instead it supports the reporting of daily exams to monitor and study the evolution of the disease, thus optimising workflow.
For medical professionals – download the take-away: https://synapse.fujifilm.eu/fujifilm-takeaway/
Read more

https://interhospi.com/wp-content/uploads/sites/3/2020/08/PRODUCT_FUJIFILM_1.jpg 420 1000 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:31:322021-01-08 12:10:17Fujifilm’s Synapse 3D provides clinical decision support, speeds up workflow during COVID-19 emergency at Pisa University Hospital

Siemens offers teamplay myCare Companion flexible telemedicine solution

, 26 August 2020/in Corona News, Product News /by 3wmedia

Siemens is bringing a new and flexible telemedicine solution to the market with its teamplay myCare Companion software. The software enables remote care for patients with chronic diseases. The teamplay myCare Companion allows healthcare providers to design their own telemedicine programs and flexibly adapt the underlying technology to their needs.
The solution has initially been used at the German Heart and Diabetes Center in Bad Oeynhausen for the care of patients with chronic heart failure.
During the COVID-19 pandemic, the occupational health and safety medical center at Mannheim University Hospital has been using teamplay myCare Companions’ documentation and communication components as a “coronavirus diary” for clinical. The staff records their health status every day and medical officers can respond quickly to any changes.
“Previously we used to receive piles of diaries in paper form, but now everything is nicely arranged for software to analyse”, said Dr. Margit Eisenbarth. medical officer. “Employees can enter their data conveniently via an app or website. That saves them valuable time, and we get an immediate overview.”
Wido Menhardt, Executive Vice President Digital Health at Siemens Healthineers, said: “Thanks to state-of-the-art telemedicine solutions like teamplay myCare Companion, a large number of patients can be cared for with a relatively low use of employee resources, and the number of unscheduled hospital visits can be reduced. That can substantially lower costs and is also conducive to better quality of life for chronically ill patients. Additional uses for the program that make life a little easier for medical officers and clinical employees in the current situation show just how flexible this software is.”
Teamplay myCare Companion basically consists of two components: an intuitive smartphone app for patients and a special workstation for medical care providers. Patients use the app to report their health status, wellness, the medications they’re taking, and their vital parameters to the nursing staff. Among other things, the program helps employees quickly identify patients whose state of health may have worsened. The attending doctors can then decidewhether a scheduled hospital visit should be moved forward or if more intensive remote medical care would be beneficial.
Siemens Healthineers supplies the software and supports healthcare providers with the design, installation, and operation of their own telemedicine centre. In addition, the company can assist with procurement of the measuring devices needed to monitor patients’ vital parameters at home (such as scales and blood pressure devices).
This telemedicine solution was developed in a partnership between Siemens Healthineers, the Austrian Institute of Technology (AIT), and TELBIOMED Medizintechnik und IT Service in Austria. The partners agreed to set up a global sales and development partnership at the beginning of 2020.
Read more

https://interhospi.com/wp-content/uploads/sites/3/2020/08/PRODUCT_SIEMENS_1.jpg 391 670 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:31:322021-01-08 12:10:19Siemens offers teamplay myCare Companion flexible telemedicine solution

ASST Vimercate Hospital installs Fujifilm’s REiLI Artificial Intelligence to speed up workflow during COVID-19 emergency

, 26 August 2020/in Corona News, Product News /by 3wmedia

Azienda Socio Sanitaria Territoriale (ASST) Vimercate Hospital in Italy has implemented Fujifilm’s REiLI artificial intelligence system to assist healthcare practitioners on the frontline in the fight against the COVID-19 pandemic.
Due to the pandemic, operations and workflows in Italian hospitals were disrupted, which significantly increased workloads. As a consolidated partner of Vimercate, Fujifilm wanted to ensure its cutting-edge tools were available to reduce the impact caused by the rapid spread of COVID-19 by assisting in speeding up workflows.
REiLI’s processing of CT scans and chest x-rays provides important support for radiologists, offering them an extremely rapid, quantitative and objective assessment of the various zones of the lungs. The chest x-ray, in particular, is the best example of applying the new AI technology, in that it produces a quick and simple examination which provides a large amount of useful information for evaluating the presence of the pulmonary parenchymal consolidation caused by the virus.
The data obtained from artificial intelligence does not replace the molecular diagnoses performed using the nasopharyngeal swab (RT-PCR), nor does it replace the analyses and diagnoses performed by the radiologist. The data, however, does provide support in reporting on daily examinations conducted to monitor and study the development of the disease, and constitute a second opinion for the operators.
Commenting on the REiLI artificial intelligence system, Marcello Intotero, Head of Radiology Structure and Diagnostic Services Department at ASST Vimercate Hospital, said: “REiLI’s support has allowed our radiologists to report examinations with greater speed and efficiency. This new technology has given great support to the workflow; all images that the artificial intelligence system identified as suspected COVID-19 were subjected to processing by the radiologist in a faster and more urgent manner.”
REiLI is integrated with the Lunit Insight CXR module for the analysis and detection of the main types of pulmonary disease. The Lunit Insight CXR3 module was updated to provide support in specifically identifying the pulmonary parenchymal consolidation caused by the virus.
Giovanni Delgrossi, Head of the IT Department at ASST Vimercate noted that during the health emergency, more than 80 chest x-rays of patients were analysed each day at the hospital. “If no priority is set for the examinations to be reported, it may take hours to identify a particular x-ray which may require prompt, immediate action from doctors. In an emergency like the current one, we need to react and act even more quickly,” he said.
Discussing Fujifilm’s REiLI AI system, Nicola Bilibio, Clinical Specialist Medical Informatics (CSE) Fujifilm Europe GmbH explained that AI is a new operating concept projected towards collaborative intelligence between machine and man. “This is a fundamental tool for optimizing workflow and for screening patients for COVID-19. During the emergency, we promptly made our most advanced technologies available to make a concrete contribution to the crisis.”

  • For more information, visit: http://reili.fujifilm.com
  • About REiLI on YouTube: https://youtu.be/M6ISuRmvQbY

Read more

https://interhospi.com/wp-content/uploads/sites/3/2020/08/fujifilm_REiLI.jpg 1238 1030 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:31:322021-01-08 12:10:19ASST Vimercate Hospital installs Fujifilm’s REiLI Artificial Intelligence to speed up workflow during COVID-19 emergency
Page 5 of 6«‹3456›

Latest issue of International Hospital

April 2024

11 December 2025

AI achieves superhuman accuracy in blood cell classification using generative diffusion models

11 December 2025

Siemens Healthineers unveils AI-powered imaging chain

10 December 2025

Psychiatry breakthrough: Genetic mapping reveals five key factors underlying 14 psychiatric disorders

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The medical devices information portal connecting healthcare professionals to global vendors

Sign in for our newsletter
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Media kit
    • Submit Press Release

Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@interhospi.com

PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Sign in for our newsletter

Free subscription